| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -4.1 | -4.9 |
| EPS (diluted, $ a share) | $-0.04 | $-0.06 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: CGTX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Cognition Therapeutics Inc: key numbers
- Share price
- $0.6388Close, Nov 16
- Market cap
- $60.8M
- Shares outstanding
- 95.1MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Cognition Therapeutics Inc
All →Cognition Therapeutics Nasdaq/NYSE Compliance Notice
Cognition Therapeutics received a deficiency notice from Nasdaq on November 3, 2026, because its common stock failed to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days. The company has until May 3, 2027, to regain compliance by having its stock price close at or above $1.00 for at least 10 consecutive business days.
- Counterparty
- Nasdaq
- Term
- 180 days
“The work we conducted with the Office of Neuroscience at the FDA during 2026 culminated in the development of a trial protocol for a planned registrational study of zervimesine (CT1812) in people with dementia with Lewy bodies (DLB). We are now evaluating our plans for manufacturing, site selection, and patient recruitment.”
Lisa Ricciardi, Cognition’s president and CEO
“At the same time, we are working with our collaborators at the Alzheimer’s Clinical Trial Consortium (ACTC) to prepare for the conclusion of the Phase 2 START Study in people with MCI and early Alzheimer’s disease. Top-line results from START are anticipated in the second half of 2027 and will inform our plans for zervimesine in Alzheimer’s disease.”
Lisa Ricciardi, Cognition’s president and CEO
Cognition Therapeutics Business Update
Cognition Therapeutics has reached alignment with the FDA on the design of its planned Phase 3 registrational study for zervimesine (CT1812) in patients with dementia with Lewy bodies (DLB). The study will focus on mild-to-moderate DLB patients using hallucinations (NPI-2) as a primary endpoint and daily function (ADCS-ADL) as a secondary endpoint.
- Counterparty
- FDA
- Term
- 9 months